-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by clinical symptoms such as abdominal pain, chronic diarrhea, gastrointestinal bleeding, and intestinal complications such as strictures and fistulas, although the exact pathogenesis of CD remains unclear.
Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by clinical symptoms such as abdominal pain, chronic diarrhea, gastrointestinal bleeding, and intestinal complications such as strictures and fistulas, although the exact pathogenesis of CD remains unclear.
The results showed that endoscopic activity was negatively correlated with serum UST trough levels (Spearman's rank correlation coefficient (ρ) = -0.
This study demonstrated that increased endoscopic activity was significantly associated with lower UST trough levels and serum albumin levels
This study demonstrated that increased endoscopic activity was significantly associated with lower UST trough levels and serum albumin levels
Original source:
Hisashi Hirayama.
Hisashi Hirayama.
Et al.
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
BMC Gastroenterology.
2022.
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
Leave a comment
